Increase (Decrease) In Earnings Per Share, Basic

No definition available.

Name:	sgmo_IncreaseDecreaseInEarningsPerShareBasic
Namespace Prefix:	sgmo_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase (Decrease) In Earnings Per Share, Diluted

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInEarningsPerShareDiluted
Namespace Prefix:	sgmo_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase (Decrease) In Net Income (Loss) Attributable To Parent

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-4

+ Details

Name:	us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

+ Details

Name:	us-gaap_ChangeInAccountingEstimateLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.

+ References

No definition available.

+ Details

Name:	us-gaap_LettersOfCreditOutstandingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarch2023Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Change in Accounting Estimate [Line Items]
Letter of credit established as a deposit		$ 900
Cash and cash equivalents	$ 78,241	$ 54,417	$ 45,204	$ 100,444
Kite Pharma, Inc. \| Change In Agreement Estimate, March 2023
Change in Accounting Estimate [Line Items]
Increase in revenue	8,900
Decrease in net loss	$ 8,900
Decreased net loss per share, basic (in dollars per share)	$ 0.06
Decreased net loss per share, diluted (in dollars per share)	$ 0.05